Weiping Deng

6.4k citations
98 papers · 2.2k indexed · 1 hit paper · h-index 21

Weiping Deng

90 papers receiving 2.2k citations

Hit Papers

Long-term benefits and risks of frontline nilotinib vs im...5632016202620192022100200300400500

Peers

Weiping Deng
Comparison fields: 5 of 130
  • Hematology 926
  • Genetics 745
  • Rheumatology 451
  • Hepatology 217
  • Oncology 261
Replace Martin E. Dowty with:
Martin E. Dowty United States
John Galivan United States
Katsuya Ikuta Japan
Hiroyuki Kuroda Japan
David Loury United States
Thomas T. Kawabata United States
Sheng Wei United States
Yi‐Chang Liu Taiwan
Sunil Sharma United States
H Riedel Germany
Weiping Deng relative to Martin E. Dowty United States Martin E. Dowty's profile →
Citations per field
00.5×10×
Martin E. Dowty · 1×
Citations per year

Countries citing papers authored by Weiping Deng

Since Specialization
Citations

This map shows the geographic impact of Weiping Deng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Weiping Deng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Weiping Deng more than expected).

Fields of papers citing papers by Weiping Deng

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Weiping Deng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Weiping Deng. The network helps show where Weiping Deng may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Weiping Deng, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Weiping Deng Line = papers co-authored together Weiping Deng links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown
#Work
1 20251
2 20255
3 20250
4 20256
5 20246
6 20241
7 202415
8 20241
9 20244
10 202380
11 20237
12 20230
13 20230
14 20232
15 202116
16 2018104
17
Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trialbreakdown →
2016563
18 201317
19 20081
20 20088

About Weiping Deng

Weiping Deng is a scholar working on Infectious Diseases, Genetics and Hematology, having authored 98 papers that have together received 2.2k indexed citations. Recurring topics across this work include SARS-CoV-2 and COVID-19 Research (16 papers), Chronic Myeloid Leukemia Treatments (9 papers), Chronic Lymphocytic Leukemia Research (8 papers), Hepatitis C virus research (7 papers), Plant-Microbe Interactions and Immunity (7 papers), COVID-19 Clinical Research Studies (6 papers), Viral gastroenteritis research and epidemiology (6 papers) and Animal Virus Infections Studies (5 papers). The work is most often cited by research in Hematology (926 citations), Genetics (745 citations) and Rheumatology (451 citations). Weiping Deng has collaborated with scholars based in China, United States and Germany. Frequent co-authors include Andreas Hochhaus, Giuseppe Saglio, Hans D. Menssen, Philipp D. le Coutre, Xuefeng Jiang, Daming Zeng, Timothy P. Hughes, Richard A. Larson, Hagop M. Kantarjian and Richard E. Clark. Their work appears in journals such as JAMA, Nature Medicine and Journal of Clinical Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026